CRANBURY, NJ ( TheStreet) -- The U.S. Food and Drug Administration refused a request from Amicus Therapeutics (FOLD) to amend the statistical plan for a failed phase III study of its experimental Fabry disease drug Amigal. As a result, Amicus is delaying the U.S. approval filing for Amigal until late 2014 or early 2015 -- after data from another phase III study is completed.
Amicus shares fell 22% to $2.50 in early Monday trading.
Last December, Amicus announced disappointing six-month results from a phase III study of Amigal in patients with Fabry disease. Forty-one percent of Amigal patients were counted as responders (meaning they had a 50% decrease in GL3 in their kidneys. By comparison, 28% of placebo patients were responded. The response trend clearly favored Amigal but the difference was not statistically significant.
Amicus met with FDA hoping to convince regulators to allow changes to the study to review Amigal's efficacy based on longer-term (12 months) response rates, as well as in certain subgroups of patients with higher baseline levels of GL3.On Monday, Amicus said FDA agreed to the changes in the study but regulator also insisted that from a regulatory standpoint, the study would still be considered a failure. This prevents Amicus and partner GlaxoSmithKline (GSK) from seeking FDA approval until more Amigal data is compiled. The two companies are conducting a second phase III study in which Fabry patients are switched from a currently approved therapy to Amigal. Results from this study are expected in the first half of 2014. Even if the study is positive, Amicus cautioned that a U.S. filing won't be completed until another meeting is held with FDA in the second half of 2014. Twelve-month data from the first phase III study are expected in the fourth quarter of this year. Amicus has enough cash on hand to continue operations into the second half of 2014. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV